Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management

References

• CorsonelloAPedoneCCoricaFIncalziRAPolypharmacy in elderly patients at discharge from the acute care hospitalTher Clin Risk Manag20073119720318360627
   PubMedGoogle Scholar
• KohYKuttyFBLiSCDrug-related problems in hospitalized patients on polypharmacy: the influence of age and genderTher Clin Risk Manag200511394818360542
   PubMedGoogle Scholar
• DoanJZakrzewski-JakubiakHRoyJTurgeonJTannenbaumCPrevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacyAnn Pharmacother201347332433223482734
   PubMed Web of Science ®Google Scholar
• Joint Commission InternationalJCI accreditation standards for hospitals [webpage on the Internet]Oak Brook, ILJoint Commission International2010 Available from: http://www.jointcommissioninternational.org/common/pdfs/jcia/IAS400_Standards_Lists_Only.pdfAccessed March 20, 2013
   Google Scholar
• MahmoodMMaloneDCSkrepnekGHPotential drug-drug interactions within Veterans Affairs medical centersAm J Health Syst Pharm200764141500150517617500
   PubMed Web of Science ®Google Scholar
• OgawaREchizenHDrug-drug interaction profiles of proton pump inhibitorsClin Pharmacokinet201049850953320608754
   PubMed Web of Science ®Google Scholar
• BlumeHDonathFWarnkeASchugBSPharmacokinetic drug interaction profiles of proton pump inhibitorsDrug Saf200629976978416944963
   PubMed Web of Science ®Google Scholar
• GersonLBTriadafilopoulosGProton pump inhibitors and their drug interactions: an evidence-based approachEur J Gastroenterol Hepatol200113561161611396546
   PubMed Web of Science ®Google Scholar
• GuglerRJensenJCOmeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitroGastroenterology1985896123512413932118
   PubMed Web of Science ®Google Scholar
• ZvyagaTChangSYChenCEvaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P4502C19Drug Metab Dispos20124091698171122648560
   PubMed Web of Science ®Google Scholar
• CaracoYTateishiTWoodAJInterethnic difference in omeprazole’s inhibition of diazepam metabolismClin Pharmacol Ther199558162727628184
   PubMed Web of Science ®Google Scholar
• GuglerRHartmannMRudiJLack of pharmacokinetic interaction of pantoprazole with diazepam in manBr J Clin Pharmacol19964222492528864328
   PubMed Web of Science ®Google Scholar
• LefebvreRAFlouvatBKarolac-TamisierSMoermanEVan GanseEInfluence of lansoprazole treatment on diazepam plasma concentrationsClin Pharmacol Ther19925254584631424419
   PubMed Web of Science ®Google Scholar
• IshizakiTChibaKManabeKComparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylationClin Pharmacol Ther19955821551647648765
   PubMed Web of Science ®Google Scholar
• NaiduMURShobhaJCDixitVKEffect of multiple dose omeprazole on the pharmacokinetics of carbamazepineDrug Invest199471812
   Web of Science ®Google Scholar
• DixitRKChawlaABKumarNGargSKEffect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteersMethods Find Exp Clin Pharmacol2001231373911413862
   PubMedGoogle Scholar
• BertilssonLTybringGWidénJChangMTomsonTCarbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19Br J Clin Pharmacol19974421861899278208
   PubMed Web of Science ®Google Scholar
• HuberRBliesathHHartmannMPantoprazole does not interact with the pharmacokinetics of carbamazepineInt J Clin Pharmacol Ther199836105215249799054
   PubMed Web of Science ®Google Scholar
• DaltonMJPowellJRMessenheimerJAJrRanitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adultsDrug Intell Clin Pharm198519129419444085354
   PubMedGoogle Scholar
• HanXMOuyangDSChenXPInducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2Br J Clin Pharmacol200254554054312445035
   PubMed Web of Science ®Google Scholar
• RostKLBrösickeHHeinemeyerGRootsISpecific and dose-dependent enzyme induction by omeprazole in human beingsHepatology1994205120412127927253
   PubMed Web of Science ®Google Scholar
• FrickAKopitzJBergemannNOmeprazole reduces clozapine plasma concentrations. A case reportPharmacopsychiatry200336312112806570
   PubMed Web of Science ®Google Scholar
• MookhoekEJLoonenAJRetrospective evaluation of the effect of omeprazole on clozapine metabolismPharm World Sci200426318018215230368
   PubMedGoogle Scholar
• HartmannMZechKBliesathHPantoprazole lacks induction of CYP1A2 activity in manInt J Clin Pharmacol Ther199937415916410235417
   PubMed Web of Science ®Google Scholar
• BondolfiGMorelFCrettolSRachidFBaumannPEapCBIncreased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patientsTher Drug Monit200527453954316044115
   PubMed Web of Science ®Google Scholar
• FalconRWKakudaTNDrug interactions between HIV protease inhibitors and acid-reducing agentsClin Pharmacokinet2008472758918193914
   PubMed Web of Science ®Google Scholar
• BurgerDMHugenPWKroonFPPharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavirAIDS19981215208020829814882
   PubMed Web of Science ®Google Scholar
• FangAFDamleBDLaBadieRRCrownoverPHHewlettDJrGluePWSignificant decrease in nelfinavir systemic exposure after omeprazole coad-ministration in healthy subjectsPharmacotherapy2008281425018154473
   PubMed Web of Science ®Google Scholar
• ZhuLPerssonAMahnkeLEffect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjectsJ Clin Pharmacol201151336837720457590
   PubMed Web of Science ®Google Scholar
• SharmaMSaravolatzLDRilpivirine: a new non-nucleoside reverse tran-scriptase inhibitorJ Antimicrob Chemother201368225025623099850
   PubMed Web of Science ®Google Scholar
• TappouniHLRubleinJCDonovanBJEffect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavirAm J Health Syst Pharm200865542242818281734
   PubMed Web of Science ®Google Scholar
• SaahAJWinchellGANesslyMLSeniukMARhodesRRDeutschPJPharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteersAntimicrob Agents Chemother200145102710271511557459
   PubMed Web of Science ®Google Scholar
• ZhouSChanELiXHuangMClinical outcomes and management of mechanism-based inhibition of cytochrome P4503A4Ther Clin Risk Manag20051131318360537
   PubMedGoogle Scholar
• BoffitoMCarrieroPTrentiniLPharmacokinetics of saquinavir co-administered with cimetidineJ Antimicrob Chemother20025061081108412461038
   PubMed Web of Science ®Google Scholar
• SaberiPRanatungaDKQuesenberryCPSilverbergMJClinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virusPharmacotherapy201131325326121361735
   PubMed Web of Science ®Google Scholar
• LuberADBrowerRKimDSilvermanRPeloquinCAFrankISteady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteersHIV Med20078745746417760738
   PubMed Web of Science ®Google Scholar
• VanHeeswijk RHoetelmansRKestensDInternational AIDS SocietyThe pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteersProceedings of the Fourth IAS Conference on HIV Pathogenesis, Treatment, and Prevention2007Sydney, Australia
   Google Scholar
• BrownKCPaulSKashubaADDrug interactions with new and investigational antiretroviralsClin Pharmacokinet200948421124119492868
   PubMed Web of Science ®Google Scholar
• BeorleguiBAldazAOrtegaAAquerretaISierrasesúmegaLGiráldezJPotential interaction between methotrexate and omeprazoleAnn Pharmacother20003491024102710981249
   PubMed Web of Science ®Google Scholar
• BezabehSMackeyACKluetzPJapparDKorvickJAccumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitorsOncologist201217455055422477728
   PubMed Web of Science ®Google Scholar
• BautersTGVerlooyJRobaysHLaureysGInteraction between methotrexate and omeprazole in an adolescent with leukemia: a case reportPharm World Sci200830431631818386155
   PubMedGoogle Scholar
• RanchonFVantardNGouraudASuspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report—should the practice be changed?Chemotherapy201157322522921597286
   PubMed Web of Science ®Google Scholar
• ChristiansUSchmidtGBaderAIdentification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomesBr J Clin Pharmacol19964131871908866917
   PubMed Web of Science ®Google Scholar
• MaguireMFranzTHainsDSA clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipientPediatr Transplant2012166E217E22021883747
   PubMed Web of Science ®Google Scholar
• HosohataKMasudaSKatsuraTImpact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patientsDrug Metab Dispos200937482182619139162
   PubMed Web of Science ®Google Scholar
• HosohataKMasudaSOguraYInteraction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5Drug Metab Pharmacokinet200823213413818445994
   PubMed Web of Science ®Google Scholar
• HosohataKMasudaSYonezawaAAbsence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control studyDrug Metab Pharmacokinet200924545846319881258
   PubMed Web of Science ®Google Scholar
• TakahashiKYanoIFukuharaYDistinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipientDrug Metab Pharmacokinet200722644144418159131
   PubMed Web of Science ®Google Scholar
• LorfTRamadoriGRingeBSchwörerHThe effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipientsEur J Clin Pharmacol200056543944011009056
   PubMed Web of Science ®Google Scholar
• DoeschAOMuellerSKonstandinMProton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetilTransplant Proc201042104243424621168674
   PubMed Web of Science ®Google Scholar
• David-NetoETakakiKMAgenaFDiminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantationTher Drug Monit201234333133622549498
   PubMed Web of Science ®Google Scholar
• KiberdBAWrobelMDandavinoRKeownPGourishankarSThe role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR studyTher Drug Monit201133112012321192310
   PubMed Web of Science ®Google Scholar
• KeesMGSteinkeTMoritzSOmeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteersJ Clin Pharmacol20125281265127221903891
   PubMed Web of Science ®Google Scholar
• DrepperMDSpahrLFrossardJLClopidogrel and proton pump inhibitors – where do we stand in 2012?World J Gastroenterol201218182161217122611308
   PubMed Web of Science ®Google Scholar
• NorgardNBMathewsKDWallGCDrug-drug interaction between clopidogrel and the proton pump inhibitorsAnn Pharmacother20094371266127419470853
   PubMed Web of Science ®Google Scholar
• BhattDLCryerBLContantCFCOGENT InvestigatorsClopidogrel with or without omeprazole in coronary artery diseaseN Engl J Med2010363201909191720925534
   PubMed Web of Science ®Google Scholar
• BatesERLauWCAngiolilloDJClopidogrel-drug interactionsJ Am Coll Cardiol201157111251126321392639
   PubMed Web of Science ®Google Scholar
• WuJJiaLTShaoLMDrug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteersEur J Clin Pharmacol201369217918722706585
   PubMed Web of Science ®Google Scholar
• NeubauerHEngelhardtAKrügerJCPantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stentingJ Cardiovasc Pharmacol2010561919720410834
   PubMed Web of Science ®Google Scholar
• FrelingerAL3rdLeeRDMulfordDJA randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteersJ Am Coll Cardiol201259141304131122464259
   PubMed Web of Science ®Google Scholar
• TunggalPNgFHLamKFChanFKLauYKEffect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trialAm Heart J2011162587087422093203
   PubMed Web of Science ®Google Scholar
• NgFHTunggalPChuWMEsomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarctionAm J Gastroenterol2012107338939622108447
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPFortJGSpaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrelAm Heart J2013165217618223351820
   PubMed Web of Science ®Google Scholar
• KileyCACraginDJRothBJOmeprazole-associated digoxin toxicitySouth Med J2007100440040217458401
   PubMed Web of Science ®Google Scholar
• GabelloMValenzanoMCBarrMZurbachPMullinJMOmeprazole induces gastric permeability to digoxinDig Dis Sci20105551255126319513837
   PubMed Web of Science ®Google Scholar
• CollettATanianis-HughesJCarlsonGLHarwoodMDWarhurstGComparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo predictionEur J Pharm Sci200526538639316153812
   PubMed Web of Science ®Google Scholar
• Pauli-MagnusCRekersbrinkSKlotzUFrommMFInteraction of omeprazole, lansoprazole and pantoprazole with P-glycoproteinNaunyn Schmiedebergs Arch Pharmacol2001364655155711770010
   PubMed Web of Science ®Google Scholar
• HartmannMHuberRBliesathHLack of interaction between pantoprazole and digoxin at therapeutic doses in manInt J Clin Pharmacol Ther199634Suppl 1S67S718793605
   PubMed Web of Science ®Google Scholar
• JaruratanasirikulSSriwiriyajanSEffect of omeprazole on the pharmacokinetics of itraconazoleEur J Clin Pharmacol19985421591619626921
   PubMed Web of Science ®Google Scholar
• JohnsonMDHamiltonCDDrewRHSandersLLPennickGJPerfectJRA randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solutionJ Antimicrob Chemother200351245345712562722
   PubMed Web of Science ®Google Scholar
• AlffenaarJWvan AssenSvan der WerfTSKosterinkJGUgesDROmeprazole significantly reduces posaconazole serum trough levelClin Infect Dis200948683919220151
   PubMed Web of Science ®Google Scholar
• LangeDPavaoJHWuJKlausnerMEffect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockersJ Clin Pharmacol19973765355409208361
   PubMed Web of Science ®Google Scholar
• DoltonMJRayJEMarriottDMcLachlanAJPosaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoringAntimicrob Agents Chemother20125662806281322391534
   PubMed Web of Science ®Google Scholar
• RossALSlainDCumpstonABryantAMHamadaniMCraigMEvaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxisInt J Antimicrob Agents201240655756123068599
   PubMed Web of Science ®Google Scholar
• AjmeraAVShastriGSGajeraMJJudgeTASuboptimal response to ferrous sulfate in iron-deficient patients taking omeprazoleAm J Ther201219318518921150767
   PubMed Web of Science ®Google Scholar
• KaramWGGoldsteinJALaskerJMGhanayemBIHuman CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymesDrug Metab Dispos19962410108110878894508
   PubMed Web of Science ®Google Scholar
• FaucetteSRZhangTCMooreRRelative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducersJ Pharmacol Exp Ther20073201728017041008
   PubMed Web of Science ®Google Scholar
• ChenYFergusonSSNegishiMGoldsteinJAIdentification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoterMol Pharmacol200364231632412869636
   PubMed Web of Science ®Google Scholar
• MugunduGMHariparsadNDesaiPBImpact of ritonavir, atazanavir and their combination on the CYP3A4 induction potential of efavirenz in primary human hepatocytesDrug Metab Lett201041455020201776
   PubMedGoogle Scholar
• MichaudVOgburnEThongNInduction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteersClin Pharmacol Ther201291347548222318618
   PubMed Web of Science ®Google Scholar
• WangLSZhouGZhuBSt John’s Wort induces both cytochrome P4503A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazoleClin Pharmacol Ther200475319119715001970
   PubMed Web of Science ®Google Scholar
• XieHGAdditional discussions regarding the altered metabolism and transport of omeprazole after long-term use of St John’s WortClin Pharmacol Ther200578444044116198664
   PubMed Web of Science ®Google Scholar
• ZuoXCZhangBKJiaSJEffects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjectsEur J Clin Pharmacol201066550350920186406
   PubMed Web of Science ®Google Scholar
• LeiHPWangGWangLSLack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizersAnn Pharmacother200943472673119299322
   PubMed Web of Science ®Google Scholar
• ZadoyanGRokittaDKlementSEffect of Ginkgo biloba special extract EGb761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteersEur J Clin Pharmacol201268555356022189672
   PubMed Web of Science ®Google Scholar
• YinOQTomlinsonBWayeMMChowAHChowMSPharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazolePharmacogenetics2004141284185015608563
   PubMedGoogle Scholar
• HuangWZhangJMooreDDA traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CARJ Clin Invest2004113113714314702117
   PubMed Web of Science ®Google Scholar
• FanLWangGWangLSHerbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazoleActa Pharmacol Sin200728101685169217883958
   PubMed Web of Science ®Google Scholar
• PaceFPallottaSCasaliniSPorroGBA review of rabeprazole in the treatment of acid-related diseasesTher Clin Risk Manag20073336337918488081
   PubMedGoogle Scholar
• MarelliSPaceFRabeprazole for the treatment of acid-related disordersExpert Rev Gastroenterol Hepatol20126442343522928894
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses:the PRISMA statementBMJ2009339b253519622551
   PubMed Web of Science ®Google Scholar